Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;15(9):1101-12.
doi: 10.1080/14760584.2016.1187566. Epub 2016 May 27.

Ebola virus disease candidate vaccines under evaluation in clinical trials

Karen A Martins  1 , Peter B Jahrling  2 , Sina Bavari  1 , Jens H Kuhn  2
Affiliations
Review

Ebola virus disease candidate vaccines under evaluation in clinical trials

Karen A Martins et al. Expert Rev Vaccines. 2016 Sep.

Abstract

Filoviruses are the etiological agents of two human illnesses: Ebola virus disease and Marburg virus disease. Until 2013, medical countermeasure development against these afflictions was limited to only a few research institutes worldwide as both infections were considered exotic due to very low case numbers. Together with the high case-fatality rate of both diseases, evaluation of any candidate countermeasure in properly controlled clinical trials seemed impossible. However, in 2013, Ebola virus was identified as the etiological agent of a large disease outbreak in Western Africa including almost 30,000 infections and more than 11,000 deaths, including case exportations to Europe and North America. These large case numbers resulted in medical countermeasure development against Ebola virus disease becoming a global public-health priority. This review summarizes the status quo of candidate vaccines against Ebola virus disease, with a focus on those that are currently under evaluation in clinical trials.

Keywords: Candidate vaccine; EBOV; EVD; Ebola virus; Ebola virus disease; Filoviridae; MCM; clinical trial; ebolavirus; filovirus; medical countermeasure; vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Kuhn JH. Ebolavirus and Marburgvirus Infections. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. Columbus, Ohio, USA: McGraw-Hill Education; 2015. pp. 1323–1329.
    1. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004;10(12 Suppl):S110–S121. - PubMed
    1. World Health Organization. Ebola Situation Reports. 2016 http://apps.who.int/ebola/ebola-situation-reports.
    1. Yang ZY, Duckers HJ, Sullivan NJ, et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000;6(8):886–889. - PubMed
    1. Hanson RP. The natural history of vesicular stomatitis. Bacteriol Rev. 1952;16(3):179–204. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources